{
  "Country": "SE",
  "PICOs": [
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Progression-free survival (PFS) and overall survival (OS)"
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) who have been treated with docetaxel or are not medically suitable for docetaxel treatment",
      "Intervention": "New medicine under assessment",
      "Comparator": "Best supportive care",
      "Outcomes": "Cost per won QALY"
    },
    {
      "Population": "Patients with advanced NSCLC after progression on prior platinum-based chemotherapy and immunotherapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Sotorasib",
      "Outcomes": "Progression-free survival (PFS) and overall survival (OS)"
    }
  ]
}